The epidemiology of hematogenous candidiasis caused by different Candida species.
The medical records of patients with hematogenous candidiasis at M. D. Anderson Cancer Center (Houston) between 1988 and 1992 were retrospectively reviewed. There were 491 episodes of infection (6 per 1,000 admissions), 79% of which occurred outside the intensive care unit setting. A significant decrease in incidence was observed among patients with leukemia over the study period, together with a relative decrease in Candida albicans and Candida tropicalis infections and an increase in Candida krusei and possibly Candida glabrata infections. In the multivariate analysis, fluconazole prophylaxis provided strong protection against the development of C. tropicalis infection (odds ratio [OR] = 0.08) and C. albicans infection (OR = 0.15), in comparison with protection against infections due to other species, but it was the single most important determinant for the relative increase in C. krusei (OR = 27.07) and C. glabrata (OR = 5.08) infections. In conclusion, there has been a substantial shift in the epidemiology of hematogenous candidiasis caused by different Candida species in recent years. Fluconazole appears to be playing a major role in this observed shift.
Abi-Said
D
D
Department of Medical Specialties, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Anaissie
E
E
Uzun
O
O
Raad
I
I
Pinzcowski
H
H
Vartivarian
S
S
D000328:Adult; D000368:Aged; D002175:Candida / Q000145:classification*; D002177:Candidiasis / Q000453:epidemiology / Q000382:microbiology* / Q000517:prevention & control; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D016469:Fungemia / Q000453:epidemiology / Q000382:microbiology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D015725:Fluconazole